CHOSA Oncology AB, a leading force in precision oncology, has announced a series of investor events scheduled for June 2025. These events aim to engage current and potential investors by showcasing the company's latest advancements in precision medicine, particularly their proprietary biomarker, Cisplatin-DRP®.

The first event will be held at the Aktiespararna- Aktiedagarna in Stockholm on June 11, 2025, where CEO Peter Buhl Jensen will present. The second event is scheduled for June 18, 2025, at the Økonomisk Ugebrev’s 'Investor Konference' in Copenhagen, with a presentation by CCO Claus Frisenberg Pedersen.

CHOSA's Cisplatin-DRP® is a groundbreaking biomarker that identifies patients most likely to respond to platinum-based chemotherapies like cisplatin and carboplatin. This innovation is crucial as it allows for more personalized treatment plans, minimizing exposure to ineffective and potentially harmful therapies.

Recent clinical trials have reinforced the efficacy of the Cisplatin-DRP® in predicting patient response to carboplatin, expanding its potential applications. These promising results are poised to be a focal point at the investor events, highlighting CHOSA's commitment to enhancing cancer treatment outcomes.

In line with their strategic growth plans, CHOSA's Board has approved a Directed Issue to raise approximately SEK 3.4 million. This capital will support the company's ongoing research and development efforts, ensuring they remain at the forefront of oncology innovation.

From an investment perspective, CHOSA presents a compelling opportunity. With a robust pipeline, proven leadership, and a strong focus on precision medicine, the company is well-positioned for future growth. Investors may consider a 'buy' stance, given the potential for significant advancements in the oncology sector and CHOSA's strategic initiatives.